Ligia Ajaime Azzalis

Ligia Ajaime Azzalis

Auto-generated profile, based on publicly available information

Ligia Ajaime Azzalis

Laboratório de Análises Clínicas, Faculdade de Medicina do ABC, Santo André, Brasil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
GVGlaucia Veiga
Glaucia Veiga
RSRaissa Daniel Machado da Silva
Raissa Daniel Machado da Silva
EPEdimar Cristiano Pereira
Edimar Cristiano Pereira
LALigia Ajaime Azzalis
Ligia Ajaime Azzalis
BABeatriz Alves
Beatriz Alves
FFFernando Luiz Affonso Fonseca
Fernando Luiz Affonso Fonseca
SUMMARY Breast cancer (BC) is one of the primary health problems worldwide. As the most common cancer in women in the world and in Brasil, behind only non-melanoma skin cancer, this neoplasm corresponds to approximately 28% of new cases per year in the country. BC also affects men, although the incidence corresponds to only 1% of total cases. Currently, most of the chemotherapeutic agents used in BC treatment are extremely toxic and cause long-term side effects. There is also a need to obtain earlier diagnoses, more accurate prognoses and make new therapies available that are more selective and effective in order to improve the current scenario. Therefore, this work sought to evaluate the importance of the biomarker survivin (Sur) in relation to BC, through the detailing of the role of Sur as a biomarker, the correlation between this protein and the prognosis of BC patients, and a summary of therapeutic strategies that target Sur for the development of new anticancer therapies.

9 June 2011 in Lung
Verified
Journal Article
Closed access
PDF file
FFFernando Luiz Affonso Fonseca
Fernando Luiz Affonso Fonseca
LALigia A. Azzalis
Ligia A. Azzalis
DFDavid Feder
David Feder
ENEverson Nogoceke
Everson Nogoceke
VJVirginia B. C. Junqueira
Virginia B. C. Junqueira
LALuiz Carlos de Abreu
Luiz Carlos de Abreu

1 October 2020
Verified
Conference Paper
Closed access
LALigia Ajaime Azzalis
Ligia Ajaime Azzalis
MRMarilena Rosalen
Marilena Rosalen
LVLetícia Moreira Viesba
Letícia Moreira Viesba
EVEverton Viesba-Garcia
Everton Viesba-Garcia

1 November 2020
Verified
Conference Paper
Closed access
LVLetícia Moreira Viesba
Letícia Moreira Viesba
MRMarilena Rosalen
Marilena Rosalen
LALígia Ajaime Azzalis
Lígia Ajaime Azzalis
EVEverton Viesba-Garcia
Everton Viesba-Garcia

1 November 2020
Verified
Conference Paper
Closed access
EVEverton Viesba-Garcia
Everton Viesba-Garcia
MRMarilena Rosalen
Marilena Rosalen
LALigia Ajaime Azzalis
Ligia Ajaime Azzalis
LVLetícia Moreira Viesba
Letícia Moreira Viesba
EVEditora V&V
Editora V&V

19 October 2019 in Current Enzyme Inhibition
Verified
Journal Article
Open access
PDF file
SZSimone Meneghetti Zatta
Simone Meneghetti Zatta
NMNeif Murad
Neif Murad
BABeatriz Alves
Beatriz Alves
LALigia Ajaime Azzalis
Ligia Ajaime Azzalis
VJVirginia Berlanga Campos Junqueira
Virginia Berlanga Campos Junqueira
FFFernando Luiz Affonso Fonseca
Fernando Luiz Affonso Fonseca
Background: The most active agents for the treatment of breast cancer are the anthracyclines whose clinical usefulness is limited by cumulative dose-dependent cardiotoxicity, which results in congestive heart failure among other limiting factors. With all the attempts to minimize chemotherapeutic cardiotoxicity, remote ischemic preconditioning (RIPC) has been considered as a potent endogenous mechanism capable of inhibiting inflammatory responses. Objective: This study aimed to verify if RIPC may be effective as prophylaxis to prevent anthracycline- induced cardiotoxicity in oncological patients. Methods: The preconditioning method was based on four to five-minute cycles of a blood pressure cuff insufflation around the upper arm (either left or right) from 200 mmHg to 250 mmHg, inducing ischemic intervals interspersed with 5 minutes of reperfusion. Results: In this work, echocardiogram results showed a ventricular mass variation that can get worse during chemotherapeutic treatment; however, in patients who had been undergoing RIPC sessions over a period of 6 months, it was observed that this change did not occur. The parameters for troponin T levels were considered; they were higher in patients who were not undergoing RIPC in relation to those who were. When both cases were compared, it was possible to infer that there was a clinically significant improvement for those who went through the procedure. Conclusion: Thus, through the analysis of this study, it is possible to conclude that RIPC is a lowcost, non-invasive procedure which brings cardiac protection for patients undergoing chemotherapy with anthracyclines, providing support in the treatment of cancer.